Hoth Therapeutics’ (NASDAQ:HOTH) lock-up period is set to expire on Wednesday, August 14th. Hoth Therapeutics had issued 1,250,000 shares in its public offering on February 15th. The total size of the offering was $7,000,000 based on an initial share price of $5.60. After the expiration of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Separately, Laidlaw began coverage on Hoth Therapeutics in a research note on Monday, May 20th. They issued a “buy” rating and a $10.00 price target on the stock.
Hoth Therapeutics stock opened at $4.83 on Wednesday. Hoth Therapeutics has a 1-year low of $3.95 and a 1-year high of $13.88. The company has a 50 day simple moving average of $5.50.
Hoth Therapeutics Company Profile
Hoth Therapeutics, Inc, a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures.
Featured Story: Dollar Cost Averaging
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.